In the EU, rivaroxaban is marketed under the trade name Xarelto®. Marketing authorization may vary from country to country. In France, rivaroxaban is approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors for stroke, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Enhance your symposium experience

Our virtual platform will help both in-room and remote attendees get the most out of this symposium

In the room? Participate in polls and ask questions to the panel via the virtual platform

Unable to attend? Why not join the symposium virtually?

Please see the back page for instructions on how to join
Chairman’s Welcome

Dear Colleagues,

I am delighted to invite you to attend this Satellite Symposium at the 18th Congress of the European Association of Hospital Pharmacists, entitled ‘Treating and Preventing Blood Clots…Practical Considerations with Rivaroxaban’. This symposium will provide an opportunity to share knowledge and experience in the use of rivaroxaban across multiple indications.

Rivaroxaban has transformed the management of thromboembolic disease, and clinical experience with the use of rivaroxaban in multiple indications is growing rapidly. An understanding of the practical management of rivaroxaban is essential in order to optimize patient outcomes and ensure cost-effectiveness within healthcare systems. During this interactive symposium, the Expert Panel will summarize key findings from the extensive rivaroxaban clinical trial programme and highlight the breadth of indications and the benefits offered by rivaroxaban to real-world practice. Data elucidating the burden of thromboembolic disease and examining the use of rivaroxaban as a cost-effective approach will be presented. Thereafter, the optimal management of patients receiving rivaroxaban therapy and practical approaches to ensuring both safety and compliance will be explored.

The Expert Panel will then answer your questions related to the practical management of rivaroxaban, as well as discuss their experiences of using rivaroxaban in daily clinical practice.

I hope that you will be able to join us for what promises to be a very engaging, interactive and informative symposium.

Kind regards,

Alexander T. Cohen

Programme

Chaired by Alexander T. Cohen
Wednesday 13 March 2013, 14:00–15:30
Amphi Bordeaux, Level 3, Le Palais des Congrès de Paris, Paris, France

14:00 Welcome and introduction
Alexander T. Cohen, UK

14:05 Breadth of indication matters…
One drug for multiple indications
Sylvia Haas, Germany

14:25 Cost matters…Cost-effective management of thromboembolic disease
Alexander T. Cohen, UK

14:45 Experience matters…
Practical management in your hospital
Marcel Levi, the Netherlands

15:05 Interactive Q&A session
Expert Panel chaired by Alexander T. Cohen, UK

15:25 Summary and close
Alexander T. Cohen, UK

“Don’t forget to join the symposium online to view the slides, take part in polls and ask questions to the panel. See the back page for instructions”